<p>在過去一個季度中，10 位分析師對 Viridian Therapeutics VRDN 表達了各種意見，提供了從看漲到看跌的多樣化觀點。</p>
<p>下表總結了他們最近的評級，揭示了過去 30 天內情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th><strong>看漲</strong></th>
<th><strong>稍微看漲</strong></th>
<th><strong>無所謂</strong></th>
<th><strong>稍微看跌</strong></th>
<th><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 41.2 美元，最高估計為 61.00 美元，最低估計為 34.00 美元。當前平均價格目標較之前的 39.70 美元上升了 3.78%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png"/></p>
<h2>分析師評級調查：詳盡研究</h2>
<p>通過最近的分析師行動分析金融專家對 Viridian Therapeutics 的看法。以下總結展示了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越市場</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>維持</td>
<td>超越市場</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上調</td>
<td>買入</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>維持</td>
<td>超越市場</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都表明他們對 Viridian Therapeutics 近期發展的反應。這一見解提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析趨勢，分析師提供定性評估，從 “超越市場” 到 “表現不佳”。這些評級傳達了對 Viridian Therapeutics 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師提供對 Viridian Therapeutics 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>將這些分析師評估與其他財務指標結合考慮，可以提供對 Viridian Therapeutics 市場地位的全面理解。保持信息靈通，做出明智的決策，參考我們的評級表。</p>
<p><strong>保持關注 Viridian Therapeutics 的分析師評級。</strong></p>
<p>如果您對跟蹤小型股新聞和表現感興趣，可以從這裏開始。</p>
<h2>深入瞭解 Viridian Therapeutics：更近一步</h2>
<p>Viridian Therapeutics Inc 是一家臨牀階段的生物製藥公司，致力於開發多種產品候選藥物，以治療患有甲狀腺眼病的患者。其產品候選藥物 VRDN-001 是一種胰島素樣生長因子-1 受體（IGF-1R）單克隆抗體（mAb），正在開發中以潛在治療甲狀腺眼病患者。</p>
<h3>分析 Viridian Therapeutics 的財務表現</h3>
<p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，反映出其規模龐大和市場認可度強。</p>
<p><strong>收入增長：</strong> Viridian Therapeutics 在過去 3 個月的收入增長顯著。截至 2024 年 9 月 30 日，該公司的收入增長率約為 <strong>19.44%</strong>。這表明公司頂線收益的顯著增加。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平，面臨一定困難。</p>
<p><strong>淨利潤率：</strong> Viridian Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面可能面臨挑戰。淨利潤率為 <strong>-89173.26%</strong>，公司在有效成本管理方面可能面臨困難。</p>
<p><strong>股本回報率（ROE）：</strong> Viridian Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-18.08%</strong>，公司在實現最佳財務回報方面可能面臨困難。</p>
<p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 低於行業基準，表明在有效利用資產方面可能面臨困難。ROA 為 <strong>-11.3%</strong>，公司可能需要解決從資產中產生滿意回報的挑戰。</p>
<p><strong>債務管理：</strong> Viridian Therapeutics 的債務與股本比率低於行業平均水平，為 <strong>0.04</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
<h2>分析師評級：它們是什麼？</h2>
<p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以達成他們的決策。</p>
<p>一些分析師還會提供關於增長預期、收益和收入等指標的預測，以進一步指導股票投資。使用分析師評級的投資者應注意，這些專業建議來自於人類，可能會存在錯誤。</p>
<p><strong>分析師現在推薦哪些股票？</strong></p>
<p>Benzinga Edge 讓您即時獲取所有主要分析師的評級上調、下調和價格目標。按準確性、上漲潛力等進行排序。<strong>點擊這裏以領先市場</strong>。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

VRDN

<p>十位分析師對 Viridian Therapeutics (VRDN) 發表了不同的看法，評級從看漲到看跌不等。最近的評估顯示情緒出現積極轉變，12 個月的平均目標價為 20.00 美元，比之前的目標上漲了 3.78%。分析師們提高或維持了評級，反映了他們對市場動態的反應。在財務方面，Viridian 的收入增長率為 19.44%，但面臨淨利潤率為-89173.26% 和股本回報率為-18.08% 的挑戰。該公司保持了 0.04 的保守債務與股本比率，表明對債務融資的依賴較低</p>

<p>10 analysts have expressed a variety of opinions on Viridian Therapeutics VRDN over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<div class="lb-trans"><p>在過去一個季度中，10 位分析師對 Viridian Therapeutics VRDN 表達了各種意見，提供了從看漲到看跌的多樣化觀點。</p>
</div><p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表總結了他們最近的評級，揭示了過去 30 天內情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th><strong>Bullish</strong></th>
<th><strong>Somewhat Bullish</strong></th>
<th><strong>Indifferent</strong></th>
<th><strong>Somewhat Bearish</strong></th>
<th><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th><strong>看漲</strong></th>
<th><strong>稍微看漲</strong></th>
<th><strong>無所謂</strong></th>
<th><strong>稍微看跌</strong></th>
<th><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.2, a high estimate of $61.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 3.78% from the previous average price target of $39.70.</p>
<div class="lb-trans"><p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 41.2 美元，最高估計為 61.00 美元，最低估計為 34.00 美元。當前平均價格目標較之前的 39.70 美元上升了 3.78%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png" alt="" original-src="https://www.benzinga.com/files/images/story/2024/1734458424_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析師評級調查：詳盡研究</h2>
</div><p>The perception of Viridian Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過最近的分析師行動分析金融專家對 Viridian Therapeutics 的看法。以下總結展示了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越市場</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>維持</td>
<td>買入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>維持</td>
<td>超越市場</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上調</td>
<td>買入</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>維持</td>
<td>超越市場</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viridian Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Viridian Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都表明他們對 Viridian Therapeutics 近期發展的反應。這一見解提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析趨勢，分析師提供定性評估，從 “超越市場” 到 “表現不佳”。這些評級傳達了對 Viridian Therapeutics 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師提供對 Viridian Therapeutics 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Viridian Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<div class="lb-trans"><p>將這些分析師評估與其他財務指標結合考慮，可以提供對 Viridian Therapeutics 市場地位的全面理解。保持信息靈通，做出明智的決策，參考我們的評級表。</p>
</div><p><strong>Stay up to date on Viridian Therapeutics analyst ratings.</strong></p>
<div class="lb-trans"><p><strong>保持關注 Viridian Therapeutics 的分析師評級。</strong></p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，可以從這裏開始。</p>
</div><h2>Discovering Viridian Therapeutics: A Closer Look</h2>
<div class="lb-trans"><h2>深入瞭解 Viridian Therapeutics：更近一步</h2>
</div><p>Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.</p>
<div class="lb-trans"><p>Viridian Therapeutics Inc 是一家臨牀階段的生物製藥公司，致力於開發多種產品候選藥物，以治療患有甲狀腺眼病的患者。其產品候選藥物 VRDN-001 是一種胰島素樣生長因子-1 受體（IGF-1R）單克隆抗體（mAb），正在開發中以潛在治療甲狀腺眼病患者。</p>
</div><h3>Breaking Down Viridian Therapeutics's Financial Performance</h3>
<div class="lb-trans"><h3>分析 Viridian Therapeutics 的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，反映出其規模龐大和市場認可度強。</p>
</div><p><strong>Revenue Growth:</strong> Viridian Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>19.44%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Viridian Therapeutics 在過去 3 個月的收入增長顯著。截至 2024 年 9 月 30 日，該公司的收入增長率約為 <strong>19.44%</strong>。這表明公司頂線收益的顯著增加。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平，面臨一定困難。</p>
</div><p><strong>Net Margin:</strong> Viridian Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-89173.26%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Viridian Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面可能面臨挑戰。淨利潤率為 <strong>-89173.26%</strong>，公司在有效成本管理方面可能面臨困難。</p>
</div><p><strong>Return on Equity (ROE):</strong> Viridian Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.08%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Viridian Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-18.08%</strong>，公司在實現最佳財務回報方面可能面臨困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 低於行業基準，表明在有效利用資產方面可能面臨困難。ROA 為 <strong>-11.3%</strong>，公司可能需要解決從資產中產生滿意回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> Viridian Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.04</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Viridian Therapeutics 的債務與股本比率低於行業平均水平，為 <strong>0.04</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
</div><h2>Analyst Ratings: What Are They?</h2>
<div class="lb-trans"><h2>分析師評級：它們是什麼？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以達成他們的決策。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析師還會提供關於增長預期、收益和收入等指標的預測，以進一步指導股票投資。使用分析師評級的投資者應注意，這些專業建議來自於人類，可能會存在錯誤。</p>
</div><p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<div class="lb-trans"><p><strong>分析師現在推薦哪些股票？</strong></p>
</div><p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <strong>Click here to stay ahead of the market</strong>.</p>
<div class="lb-trans"><p>Benzinga Edge 讓您即時獲取所有主要分析師的評級上調、下調和價格目標。按準確性、上漲潛力等進行排序。<strong>點擊這裏以領先市場</strong>。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

解析 Viridian Therapeutics：10 位分析師分享他們的看法